Robert H. Jones, who founded Triple J in 1984 and has served as chief executive officer since its inception, is stepping down from the CEO role, according to a release from Triple J Enterprises ...

MIAMI, April 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the ...

The investment would fund the chips and servers needed to burnish its core offerings, including Search, while supporting the development of AI services such as its Gemini model, CEO Sundar Pichai ...

TORONTO--(BUSINESS WIRE)-- VerticalScope Holdings Inc. (FORA:CA ... a trust established for the benefit of Founder, Chair and CEO, Rob Laidlaw or his family, acquired ownership of an additional ...

TORONTO, April 10, 2025--(BUSINESS WIRE)--VerticalScope Holdings Inc. ("VerticalScope" or the ... for the benefit of Founder, Chair and CEO, Rob Laidlaw or his family, acquired ownership of ...

SALT LAKE CITY - Clene Inc. (NASDAQ:CLNN), a clinical-stage biopharmaceutical company with a market capitalization of $22.84 million and currently trading near its 52-week low, announced significant ...

About HUMBL, Inc. HUMBL, Inc. is shifting toward a shareholder value-centric model under the leadership of CEO Thiago Moura, Principal of Ybyra Capital — a Brazilian holding company with ...

Clene (CLNN) announced new evidence of remyelination and neuronal repair in MS participants following treatment with CNM-Au8 30 mg from analyses of the VISIONARY-MS Trial long-term open-label ...

Clene (along with its subsidiaries,“Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate ...